Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 22Colorectal Neoplasms 19Pancreatic Neoplasms 15Stomach Neoplasms 14Rectal Neoplasms 10Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Esophageal Squamous Cell Carcinoma 7Esophageal Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Locally Advanced Rectal Cancer 6Carcinoma, Non-Small-Cell Lung 6Liver Neoplasms 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Sarcoma 4Melanoma 4Lung Neoplasms 4Gastrointestinal Stromal Tumors 4Endometrial Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Neoplasms 2Mesothelioma 2

Interventions

spartalizumab 1montanide ISA 51 1liposomal doxorubicin 1Taxes 1Surveys and Questionnaires 1Standard of Care 1Radiosurgery 1Quality of Life 1Quality Assurance, Health Care 1Psychology, Positive 1Practice Guidelines as Topic 1Platinum 1Patient Reported Outcome Measures 1Palliative Care 1Paclitaxel 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Methods 1Metastasectomy 1Lomustine 1Irinotecan 1Ipilimumab 1Interleukin-2 1Immunotherapy 1Gemcitabine 1Drug Therapy 1Doxorubicin 1Cyproheptadine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × spartalizumab × Gastrointestinal × Clear all
NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡